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infection. ConClusions: Introducing QIV into the immunization program of the 
United States would prevent a substantial number of hospitalizations and deaths. 
Moreover, cost-effectiveness was shown to be favorable when a cost-effectiveness 
threshold of US$50,000 is applied.
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Cost-UtIlIty ANAlysIs of DolUtegrAvIr ComPAreD to rAltegrAvIr 
IN treAtmeNt NAIve AND treAtmeNt exPerIeNCeD PAtIeNts IN slovAk 
settINgs
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objeCtives: Approximately 483 patients in Slovakia are living with HIV, with 68 
new infections in 2013. Raltegravir (RAL) is reimbursed for HIV-1-infected treatment-
naive (TN) and treatment-experienced (TE) patients in Slovakia. The objective of this 
analysis was to determine the cost-effectiveness of dolutegravir (DTG) relative to 
RAL. Methods: This study is based on the Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation model. A microsimulation approach simulates the outcome 
of anti-retroviral therapy by following virological suppression and CD4+ cell count 
throughout patients’ lifetime. Each treatment was assigned its specific efficacy, 
adverse events rates, and cardiovascular risk according to lipid parameters evolu-
tion; and costs and quality of life values were allocated by CD4+ cell count categories 
and attached to specific events. The analysis was performed from payer’s perspec-
tive in Slovak settings. Results: Over a lifetime, in TN patients the estimated total 
costs for the DTG strategy compared with the RAL were lower (220,731€ versus 
222,079€ ). The savings for DTG are mostly associated to the lower drug acquisition 
cost. The life expectancy was similar for the DTG and RAL (31.23 years and 30.82 
years). This translated into 0.057 QALYs. DTG was dominant treatment strategy in 
TN patients. In TE patients, the estimated total costs were slightly higher for the 
DTG strategy compared with the RAL (192,682€ versus 188,059€ ). These additional 
costs for the DTG are related to patients living longer with DTG over RAL (19.16 years 
versus 18.30 years). An increment of 0.275 QALYs for DTG was gained. The ICUR for 
the comparison of DTG and RAL was 16,805 € per QALY, which is below the threshold 
19,320€ defined as the limit at which an intervention would be considered as cost-
effective in Slovakia. ConClusions: At the proposed price and when compared to 
RAL, DTG is dominant in TN patients and cost-effective in TE patients.
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objeCtives: The aim of this exercise is to evaluate the cost-effectiveness of 
rotavirus vaccination when introduced amongst children as part of the National 
Immunization Program of Libya. Methods: We used a published simple decision 
tree model about rotavirus disease and the impact of vaccination. The model has 
been adapted to the Libyan situation for analyzing the cost-effectiveness of the 
vaccine among a birth cohort of 160,000 children followed over an at risk period of 
5 years. The evaluation of diarrhea events in 3 public hospitals helped to estimate 
the burden of rotavirus patients confirmed with lab testing during the period from 
August 2012 to April 2013. The economic analysis was done from 2 perspectives: 
health provider and patient. Uni-variate sensitivity analyses were conducted to 
assess the uncertainty in some of the variables in the model. Results: The evalu-
ation study of the 3 hospitals reported 545 diarrhea patients aged below 5 years 
old amongst whom 311 or 57% were rotavirus positive. The societal cost to treat a 
rotavirus diarrhea event was estimated at US$ 661/event. With the simple model we 
estimated that with a vaccine coverage rate of 98%, the vaccine may avoid 47,000 
rotavirus diarrhea events in the birth cohort over a period of 5 years. The estimated 
cost offset is around US$ 2 million. From a health care perspective including only 
direct medical cost the incremental cost-effectiveness ratio (ICER) with a vaccine 
price of US$ 27 per course was US$ 8,972 per QALY gained. This result is below 
the Libyan Gross Domestic Product (GDP) per capita of US$ 10,132. From a societal 
perspective the analysis shows cost savings of around US$ 16 per child in the birth 
cohort. ConClusions: The economic model shows that rotavirus vaccination 
could be an economically attractive intervention for Libya when compared with 
no vaccination.
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objeCtives: The presented economic model estimates costs and benefits of a 
new in vitro diagnostic kit for infective endocarditis (IE), developed by Hutman 
Diagnostics AG (Basel, Switzerland). The product applies molecular diagnos-
tics to detect bacteria in cardiac tissue. In order to assess the potential financial 
and economic performance of the novel kit as compared to standard micro-
biological cultures (MC), a health economic study for Switzerland has been con-
ducted. Methods: As the kit provides results within 4-6 hours after sampling 
instead of 2-3 days by MCs, three outcome scenarios for aetiopathology of IE were 
investigated by establishing a decision tree and potential economic savings were 
examined. The outcome spectra and their economic performance were assessed 
for both diagnostic methods. The first scenario includes decreased hospitalisation 
and earlier specific antibiotic treatment due to quicker diagnosis. The second sce-
nario focuses on the avoidance of reoperation, while the third scenario includes 
the mitigation of mortality. The quantitative model uses statistical data obtained 
from literature and interviews with clinical experts. Parameters quantified were e. g. 
capital and labour costs, costs for antibiotic treatment and productivity losses. 
objeCtives: To evaluate the cost-effectiveness of a new generation integrase 
inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and 
INI-naïve HIV adults with at least two- classes resistance, compared to raltegravir 
(RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation (ARAMIS) model. Methods: ARAMIS is a microsimula-
tion model using 500,000 simulations with a lifetime analytic time horizon and a 
monthly cycle length. Markov health states were defined by HIV health state (with 
or without opportunistic infection). The initial cohort, efficacy and safety data 
of the model were derived from SAILING, a phase III pivotal study. Antiretroviral 
treatment (ART) algorithms were based on French guidelines (2013) and experts 
opinion according to patients’ treatment history, including INI resistance status. 
Costs were mainly derived from the study by Sloan et al. (2012), which included 
routine HIV and opportunistic infection care, and death. Results: The ARAMIS 
model indicates that DTG compared to RAL over a life time is associated with 
additional quality-adjusted life years (QALY; 10.751 versus 10.406, 0.345 difference) 
and additional costs (€ 391,273 versus € 385,568, € 5,705 difference). DTG increased 
costs are mainly related to a 9.1-month increase in life expectancy for DTG com-
pared with RAL, and consequently a longer time spent on ART. The incremental 
cost-effectiveness ratio (ICER) for DTG compared with RAL is € 16,526 per QALY and 
€ 15,341 per life year. About 83% and 14% of total lifetime costs were associated 
with ART and routine HIV care respectively. Univariate deterministic sensitiv-
ity analyses demonstrated the robustness of the model with ICER varying from 
€ 11,038 to € 48,197 per QALY. ConClusions: DTG is a cost-effective strategy in the 
management of TE patients in France considering a collective perspective. These 
results are mainly explained by the superior efficacy of DTG reported in SAILING 
and its higher genetic barrier to resistance relative to RAL.
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HeAltH servICe (NHs)
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objeCtives: In 2012, NICE recommended protease inhibitors as first line treat-
ment for G1 HCV infection. The objective of the analysis was to assess the cost-
utility of SMV/PR versus recommended comparator regimens used to treat G1 and 
G4 patients in the NHS. Methods: The model involved a treatment phase fol-
lowed by a post-treatment Markov phase, capturing lifetime outcomes according 
to whether sustained virologic response (SVR) had been achieved. SMV/PR was 
compared with PR, telaprevir + PR (TVR/PR), and boceprevir + PR (BOC/PR) in G1 
treatment-naïve and treatment-experienced patients. In G4, SMV/PR was compared 
with PR. Dosage regimens, including response-guided therapy and futility stopping 
rules, were based on the EMA approved labels. G1 SVR estimates were derived from 
a mixed treatment comparison; a matching-adjusted indirect comparison was used 
for G4. Patient baseline characteristics were drawn from a UK HCV dataset analy-
sis and clinician opinion. Health state transition probabilities, utilities and health 
state costs were drawn from published UK analyses. Sensitivity analyses were con-
ducted to assess uncertainty around estimated costs and quality-adjusted life years 
(QALY). Results: The G1 model yielded an ICER for SMV/PR vs PR of £14,206/QALY 
for treatment-naïve and £9,793/QALY for treatment-experienced patients. SMV/PR 
dominated TVR/PR and BOC/PR in both patient groups. In G4, the ICER for SMV/PR 
vs PR was £20,791/QALY and £11,662/QALY for treatment-naïve patients using the 
two most appropriate studies for matching. The ICER was £12,070/QALY and £8,896/
QALY for treatment-experienced patients. In both models, multivariate probabilistic 
sensitivity analysis revealed that at a willingness to pay of £20,000/QALY, SMV/PR 
had the highest probability of being the most cost effective intervention, regardless 
of treatment experience. Results were robust to univariate and scenario sensitivity 
analyses. ConClusions: Compared to other regimens currently available within 
the NHS, SMV/PR is a cost-effective option to treat G1 and G4 HCV patients, regard-
less of treatment experience.
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bACKGRound: Currently used trivalent influenza vaccines (TIVs) contain two 
strains of influenza A and one strain of influenza B. However, co-circulation of two 
distinct B lineages and difficulties in predicting which lineage will predominate 
in the next season have led to frequent B-strain mismatches. Newly registered 
quadrivalent influenza vaccines (QIVs) include two B strains and might therefore 
provide wider protection. objeCtives: To evaluate the cost-effectiveness of using 
QIV versus TIV for routine influenza vaccination in the United States (US) during 
the next 20 years. Methods: A dynamic transmission model was used to estimate 
the additional protection offered by QIV over TIV against symptomatic influenza 
B disease. Subsequently, we used a decision tree model to determine the cost-
effectiveness of replacing TIV with QIV from a societal perspective. US data on 
influenza-related disease outcomes and corresponding costs were derived from 
published sources (e. g. Molinari et al. 2007). Results: Over 20 years, replacing TIV 
with QIV is predicted to prevent 13.3 million influenza B cases. According to our 
model this resulted in a reduction of 113,000 hospitalizations and 13,200 deaths. 
Moreover, 200,000 quality- adjusted life-years (QALYs), US$3.1 billion in medical 
costs and US$0.6 billion in indirect costs were saved. The base case estimate of 
the incremental cost-effectiveness ratio (ICER) was US$29,000 per QALY gained. 
Economic parameters with highest impact on the ICER were vaccine price, QALY 
loss due to influenza and probability of hospitalization or death given symptomatic 
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had STD data and 1,985 had LTD data during year following diagnosis. Of these 
87% had at least one day of ABS, 21% at least one STD claim and 2% at least one 
LTD claim. Total ABS costs in the year following the HCV diagnosis were $17,439. 
Among those with claims, STD costs during year following diagnosis were $42,149 
and LTD costs were $50,422. A smaller subset of patients had productivity data 
available for the 2 year period following diagnosis (n= 215 [ABS], n= 748 [STD], n= 670 
[LTD]). Costs during year 2 were similar to first year cost- approximately $21,400 for 
ABS, $42,700 for STD and $55,500 for LTD. ConClusions: Novel treatments can be 
costly but potential reductions in productivity losses may offset these costs. Payers 
should consider broad and long-term impact of these medications when making 
reimbursement decisions.
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objeCtives: Patients treated with triple therapy regimens of a protease inhibi-
tor (PI), pegylated interferon and ribavirin, require monitoring to assess treatment 
response (HCV-RNA assays) and determine adverse event development (clinical 
review and laboratory tests). The aim of this study was to examine resource uti-
lisation associated with treatment of patients with HCV genotype-1 managed in 
an ambulatory hospital-based setting. Methods: Data on resource utilisation for 
patients prospectively enrolled in the Irish Hepatitis C Outcomes and Research 
network (ICORN) Treatment Registry, who reached end of treatment (EOT) were gath-
ered. Data on 1) attendances to outpatient clinics for clinical assessment, 2) labora-
tory tests (FBC, liver profile etc.) and 3) HCV-RNA assays were quantified. Results: 
A total of 50/241 patients have reached EOT to date. Telaprevir accounts for 36 
patients, of whom 30% fulfilled criteria for response guided therapy (RGT), while 29% 
of boceprevir-treated patients fulfilled criteria. A total of 1371 outpatient clinic visits 
were recorded for patients to EOT (mean 29.3 (range 10-51) (SD = 9)). There were 3481 
individual laboratory tests undertaken. A full blood count is the most commonly 
ordered investigation, n= 1179 (costs incurred € 18,864). A total of 382 HCV-RNA PCR 
assays were completed to EOT (mean of 7.10 (range 4-11 (SD = 2)) per patient. This 
was 250 in excess of expected numbers of HCV-RNA assays from SPC instruction. It 
was estimated that adherence to mandated HCV-RNA assays would result in cost 
savings of approximately € 9,000 or € 180 per patient treated. ConClusions: There 
is significant resource utilisation associated with the treatment of HCV patients in a 
hospital-based setting. Cost savings may be generated by the development of guid-
ance on laboratory monitoring, and careful adherence to decision rule time points. 
This may have implications for guideline development for monitoring of patients 
treated with new agents for HCV in the near future.
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objeCtives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia. Methods: Direct costs were estimated from a payer 
perspective by using a micro-costing approach of all relevant resources used to 
manage patients with HCV genotype 1 since the diagnosis for a lifetime perspective. 
Resources and clinical practice were identified, measured and valued for nine health 
states. Resource use and clinical patterns were validated with a panel of experts in 
managing HCV patients by applying a comprehensive survey. Each of the resources 
was valued based on standard national public lists of fees in Colombian pesos (when 
the list of fees was released? Is it up to date or not?). Total costs for each of the health 
states of the disease were calculated for a one year time horizon. Results: Direct 
cost were presented in US Dollars using the average year to date exchange rate (USD 
1 = COP 1,974). Estimated average direct cost for each health state per year: non 
diagnostic HCV (USD 512), chronic HCV F0-F3 (USD 1,440), compensated cirrhosis 
(USD 976), decompensated cirrhosis (USD 10,782), hepatocellular carcinoma (USD 
10,263), liver transplantation (USD 28,883), post-transplant (USD 1,933), monitoring 
drug therapy for HCV and the management of adverse events (USD 1,020), death 
(USD 15,538). ConClusions: Chronic HCV infection represents an important eco-
nomic and humanistic burden for health systems in the world. This micro-costing 
study provides valuable information for further economic cost of illness analysis 
from the Colombian payers setting. It also reflects severity and economic impact 
of HCV related health states.
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objeCtives: Studies on medical resource utilization (MRU) and related costs are 
important for evaluating the potential patient management and cost-effectiveness 
implications of antiviral treatments for Hepatitis C virus (HCV) infection. The objec-
tives of this study were (i) to compare the MRU and related costs for two treatment 
approaches, (ii) to identify the main drivers of resource use and costs, and (iii) to 
assess the effect of various treatment regimen attributes on MRU-related costs 
in a UK clinical setting. Methods: The analysis used data collected alongside 
the simeprevir (SMV) phase III trials for treatment-naïve genotype 1 HCV-infected 
patients; these data covered outpatient consultations with specialists, emergency 
The potential cost savings were summarised for a single patient and up-scaled for 
Switzerland. Results: They are estimated to add up to approximately 9 Mio CHF 
for Switzerland for all three scenarios. Scenario 2 contributed most with about 6.5 
Mio CHF (70%). For a single patient potential savings of about 10k CHF resulted for 
scenario 1 and 700k CHF for scenarios 2 and 3. The major share of potential savings 
accrues from adjusted antibiotic treatment and from avoidance of productivity 
losses. ConClusions: Even though these results are preliminary and partly based 
on assumptions, it is expected that the economic advantages are still attractive even 
when savings might be partly lower. Nevertheless, it is desirable to verify assump-
tions and potentials by clinical trials and pilot studies.
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objeCtives: Vaccination is the best way to prevent from life-threatening and 
debilitating infectious diseases that still lead to a huge epidemiological and eco-
nomic burden to societies. The French health authorities have recently decided 
to implement a “rendez-vous” in the vaccination calendar for individuals aged 65 
years old, to achieve optimal vaccination coverage rates and improve protection for 
elderly population against diphtheria, tetanus, seasonal influenza, pneumococcal 
diseases, pertussis and herpes zoster. The objective of this study was to assess from 
a governmental perspective the return on investment of the 65 year-old’ “rendez-
vous vaccinal” in France. Methods: A cohort model was developed to compare 
the mortality, morbidity, lifetime earnings and transfers of a cohort aged 65 with 
or without vaccination. The incremental total discounted lifetime direct and indi-
rect tax revenue gained, the reduction in direct medical and social insurance costs 
resulting from the vaccinations were estimated and compared to vaccination budg-
ets. Uncertainty was handled using univariate sensitivity analyses on vaccination 
coverage, epidemiological data, economic parameters and discount rates. Results: 
From the French government’s point of view, vaccinating individuals aged 65 years 
old age is estimated to produce favorable benefit cost-ratios [~1 up to 3]. The results 
suggest that every euro invested in vaccination is expected to at-least be paid back 
to the government due to increased tax revenues, social insurance and health care 
cost-savings. ConClusions: This macro-economic analysis approaches vaccina-
tion as an investment rather than a cost. From the French Government’s point of 
view, promoting actively vaccination for 65 year-old individuals in France will favor 
healthy ageing while producing positive returns on investment.
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objeCtives: While the life expectancy of timely antiretrovirally treated HIV 
infected adults converges to that of the general population, there are still imbal-
ances with regard to the labor market [Worthington et al. (2011); Dray-Spira et 
al. (2008); Rabkin et al. (2004); Goldman, Bao (2004)]. Previous studies of a French 
cohort find that unemployment of HIV patients is significantly related to health 
related factors such as the number of CD4 cells [Dray-Spira et al. (2007); Dray-
Spira et al. (2005)]. Based on data of a German cohort we aim to analyze drivers 
of unemployment of HIV infected individuals receiving antiretroviral therapy in 
specialized centers in Germany. Methods: We prospectively surveyed 656 HIV 
patients in the age of 18-60 over two years and collected data on potential factors 
that influence the propensity of unemployment (e. g. age, educational background, 
and disease related factors). By means of a logistic regression we identify signifi-
cant determinants of unemployment. Results: The unemployment rate within 
our sample is 29.9% which is much higher than the overall German unemployment 
rate of 6.6%. A poor level of education, concomitant mental diseases, and most of 
all advanced stage of HIV disease significantly determine the likelihood of being 
unemployed. Even controlling for other determinants of unemployment, moving 
from CDC stage A to CDC stage C increases the probability of unemployment 
by 180%. ConClusions: We confirm the results of earlier studies that health 
related factors among HIV patients significantly affects the probability of being 
unemployed. Specifically, the stage of HIV disease seems to be a good predictor of 
unemployment. From a health economic point of view, earlier start of antiretroviral 
treatment and deceleration of disease progression is not only beneficial for the 
patient but also for the economy as a whole.
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objeCtives: Payers, including employers, are struggling to balance cost of novel 
therapies with long-term benefits of the treatments. The goal of this analysis is 
to examine the potential benefit of treating patients with Hepatitis C virus (HCV) 
by evaluating indirect costs during the first year following diagnosis. Methods: 
Employed patients with HCV were identified using the Truven Health Analytics 
Health and Productivity Management Database from 2010-2012. Presence and 
number of days associated with absenteeism (ABS), short-term disability (STD) and 
long-term disability (LTD) were evaluated among patients with HCV and at least 12 
months of continuous enrollment for the year following diagnosis. Costs associated 
with reduced productivity were monetized using an average hourly wage (ABS) and 
a proportion of that wage (70% for STD/LTD) and are reported in US$. Results: A 
total of 3,250 patients met the study inclusion criteria (mean age: 51 years; 67% 
male). Availability of productivity data varied - 588 employees had ABS data, 2,175 
